After it was shown that IKKβ is more critical than IKKα in activating the NF-ĸB pathway, a number of chemical entities that commonly function as IKKβ selective inhibitors were developed and tested for anti-cancer efficacy [38, 39]. The gene discussed is IKBKB; the disease is cancer.